The semaglutide impurity des-14-Leu-SMT is a characteristic structural defect impurity produced during the synthesis or degradation of semaglutide (a new long-acting GLP-1 receptor agonist hypoglycemic drug). The impurity molecule specifically lacks the leucine (Leu) residue at the 14th position, while retaining the key SMT (octadecane dioic acid side chain) modification structure. As an important process-related impurity, its presence may affect the complete conformation and receptor binding properties of the drug molecule. During drug development and quality control, this impurity needs to be strictly monitored by methods such as HPLC-MS to ensure that the quality of the raw materials and finished products meets the requirements of the ICH guidelines.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Glu-Gly-Gln-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HHAEGTFTSDVSSYEGQAKKEFIAWLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C183H284N51O56S |
Molecular weight |
4034.16 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |